NCT07924345
Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Secondary endpoints: 4 to 1
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
The proportion of study participants who achieve the LDL-C treatment target at Week 24, according to the dyslipidemia treatment guidelines
Timeframe: Day 1 to week 24
Secondary (1)
The proportion of study participants who achieve the LDL-C treatment target at Week 48, according to the dyslipidemia treatment guidelines.
Sites
1 site in 1 country
- HK inno.N CorporationSeoul, South Korea